ClinicalTrials.gg
SuspendedNCT05924594Updated May 5, 2026

Phase 3 Efficacy and Safety Laboratory Classroom Study in Pediatrics (6-12) With ADHD Using CTx-1301

A Phase 3 interventional study of CTx-1301 - Dexmethylphenidate 6.25mg and CTx-1301 - Dexmethylphenidate 12.5mg in ADHD, ADHD - Combined Type and Attention Deficit Hyper Activity, sponsored by Cingulate Therapeutics. Suspended at 3 sites in United States. Open to participants aged 6 Years to 12 Years. Per ClinicalTrials.gov, last updated 2026-05-05.

Sponsored by Cingulate Therapeutics · Phase 3, Interventional, and Treatment

Why this study was suspended
Continuation of the study is not required for NDA submission via the 505(b)(2) pathway

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
45
Allocation
Randomized
Ages
6 Years to 12 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 807 studies in Attention Deficit Disorder with Hyperactivity with a site in United States — 98 open to participants now, 116 under way, 5 of them phase 3. Attention Deficit Disorder with Hyperactivity · United States.

Enrollment
431st of 706
45 · median 70
Started
2023
with 29 others
Phase 3
121 of 807
4 open now
Registered
699th of 807
by date

Among the 807 studies in Attention Deficit Disorder with Hyperactivity with a site in United States, this one is the 431st largest by enrollment of the 706 interventional ones that give a count, is one of 30 that started in 2023, is one of 121 in phase 3, and was the 699th registered.

Attention Deficit Disorder with Hyperactivity

1,817 studies on the registry are indexed under Attention Deficit Disorder with Hyperactivity; 295 are open to participants now.

Browse Attention Deficit Disorder with Hyperactivity studies →

Open to participants now

98 of the 807 studies in Attention Deficit Disorder with Hyperactivity with a site in United States are open now. Recruiting first, the newest first:

93 more — sign in →

All 98 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 201 Attention Deficit Disorder with Hyperactivity studies recruiting now, 27 (13%) set no upper age limit and 169 (84%) stop at 75 or younger; 141 take children under 18; 55 take healthy volunteers.

This study: 6 Years to 12 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 807 studies in Attention Deficit Disorder with Hyperactivity with a site in United States, or all of them as a file.
02

Study summary

The goal of this clinical trial is to evaluate the efficacy and safety of CTx-1301 in children (6-12) with ADHD in a laboratory classroom setting.

Read the detailed description

A Phase 3, dose-optimized, randomized, double-blind, placebo-controlled, dose-optimized, parallel efficacy and safety laboratory classroom study in children (6-12) with ADHD.

The study will be comprised of a screening period, a dose-optimization phase, a double-blind randomized phase, and a safety follow-up phase. Subjects will undergo a screening visit prior to entering into a 8-week dose-optimization phase. During the dose-optimization phase, subjects will have weekly visits and will be titrated to doses ranging between 6.25mg-37.5mg of CTx-1301. Eligible subjects will be randomized phase to their optimal dose or placebo in a 1:1 ratio at the end of Visit 10 completing the practice laboratory classroom study. Subjects will take their assigned/randomized dose over the following 7-day period. On the 7th days subjects will complete the full laboratory classroom study. The duration of the full laboratory classroom study will be approximately 15 hours. Subjects will have an in-clinic safety follow-up visit within 7 days after the full classroom day.

03

Conditions studied

  • ADHD
  • ADHD - Combined Type
  • Attention Deficit Hyper Activity
  • Attention Deficit Hyperactivity Disorder
  • Attention Deficit Disorder With Hyperactivity
  • Attention Deficit Hyperactivity Disorder Combined
  • Attention-deficit Hyperactivity
04

Who can participate

Ages eligible
6 Years to 12 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female subjects between 6 and 12 years of age (inclusive) at the time of consent.
  2. Subject must have a body weight between the 5th and 95th percentile (≥5th percentile and ≤95th percentile) for their respective age and sex.
  3. Subject is unsatisfied with his/her current pharmacological therapy for treatment of ADHD or not currently receiving pharmacological therapy for ADHD. Inclusion of subjects who are naïve to pharmacological therapy for ADHD or are newly diagnosed with ADHD is permitted.
  4. Females of must have a negative serum b-human chorionic gonadotropin pregnancy test at Screening. Child-bearing potential is defined as any female who has had their first period or is 12 years or older (or will be 12 during the study). Female of childbearing potential or that become child-bearing potential during the study must agree to use a highly effective, medically acceptable form of for 30 days prior to Screening until at least 30 days after the last dose of study drug. Alternatively, subject may remain abstinent until at least 30 days after the last dose of study drug. Episodic abstinence is not reliable to avoid pregnancy, so is not considered a highly effective contraceptive method. Investigator discretion should use judgement and familiarity with the subject's "preferred and usual lifestyle" to assess if reporting of abstinence may be trusted to achieve required effectiveness. Male subjects with female partners must agree at Screening to remain abstinent or agree to use an effective and medically acceptable form of birth control from Screening to 90 days after the last dose of study drug.
  5. Subject must be in general good health defined as absence of any abnormalities as determined by the Investigator based on physical and neurological examinations, vital signs, ECGs, medical history, and safety laboratory tests at screening. If any of the exams or tests are not within the laboratory reference range, the Investigator must assess and determine if clinically significant.
  6. Subject's intellectual function is at an age-appropriate level, as deemed by the Investigator.
  7. Subjects need to be able to perform at least the basic level of problems on the PERMP pre-test with at least 5.5 questions answered correctly per minute performed at Visit 2.
  8. Subject must meet - Fifth Edition (DSM-5) criteria for the primary diagnosis of ADHD or any of the three presentations (combined, inattentive, or hyperactive/impulsive presentation) upon clinical evaluation and confirmed by the MINI International Neuropsychiatric Interview of Children and Adolescents (MINI-KID). The MINI-KID should also be used to evaluate any other psychotic disorders.
  9. Subject must score 28 or higher on the ADHD-RS-5 scale at the screening visit (Visit 1) and Baseline visit (Visit 2). For subjects requiring washout of ADHD medications, adequate of stimulant ADHD medications will be defined as no medication for the previous 5 days. Adequate washout of non-stimulant ADHD medications will be defined as no medication for the previous 21 days.
  10. Subject must have a score of 4 (moderately ill) or higher on the clinician-administrated Clinical Global Impressions-Severity (CGI-S) scale at screening (Visit 1). For subjects requiring washout of ADHD medications, adequate washout of stimulant ADHD medications will be defined as no medication for the previous 5 days. Adequate washout of non-stimulant ADHD medications will be defined as no medication for the previous 21 days.
  11. Subject must be able and willing to wash out of stimulant ADHD medications (except study drug as indicated per protocol), including herbal medication, from 5 days prior to the start of the dose optimization phase (Visit 2) and for the duration of the entire study, defined as completion of the safety follow-up visit. Additionally, subject must be able and willing to wash out from non-stimulant ADHD medications 21 days prior to the start of the dose optimization phase (Visit 2) and for the duration of the entire study, defined as completion of the safety follow-up visit.
  12. Subject and parents/legal guardians, and/or caregiver (if applicable) must be able to read, write, speak, and understand English and be able to communicate with the Investigator and study coordinator in a satisfactory fashion and complete any study-related materials. Subject and parents/legal guardians, and/or caregivers (if applicable) must plan to be available for the entire duration of the study.
  13. One or more of the parents/legal guardians, or caregivers of the subject must voluntarily give written permission for him/her to participate in the study.
  14. Subject must provide written assent prior to study participation
  15. Subject, subject's parents/legal guardians, and/or caregivers (if applicable) must understand and be willing and able to comply with study procedures as well as the visit schedule. If the subject is cared for by a caregiver for relevant portions of the day, the caregiver may be more suitable for certain assessments, and the caregiver will need to agree to the applicable procedures and visits. The most appropriate assessor should be determined prior to the double-blind, randomized, efficacy portion. The assessor for each individual subject should be the same assessor throughout the double-blind, randomized, efficacy portion of the study.
  16. Subject must be able to swallow the CTx-1301 tablet as evidenced by ability to swallow a similar size tablet (placebo) at screening.

Exclusion criteria

Exclusion Criteria:

  1. If female and of , the subject must not be pregnant or breastfeeding at any time during the study or for 30 days following the completion of the study. If of child-bearing potential, urine hCG tests will be administered at protocol-specified time points. Any positive pregnancy test during the study will exclude them from further participation in the study.
  2. Subject has any psychiatric diagnosis of bipolar I or II disorder, major depressive disorder, conduct disorder, disruptive mood dysregulation disorder (DMDD), intellectual disability, obsessive-compulsive disorder, eating disorder, anxiety disorder (including generalized anxiety disorder), any history of psychosis, autism spectrum disorder, a history of motor or vocal tics or Tourette's Syndrome, confirmed genetic disorder with cognitive and/or behavioral disturbances, or any other diagnosis/significant medical history that at the discretion of the Investigator excludes the subject from entry into the study.
  3. Subject has evidence of any chronic disease of the central nervous system (CNS) such as tumors, inflammation, seizure disorder (excluding febrile seizures), vascular disorder, potential CNS-related disorders that might occur in childhood, or history of persistent neurological symptoms related to a serious head injury.
  4. Subject has any and/or unstable/uncontrolled medical abnormality, chronic medical condition, persistent neurological symptoms, history of cardiovascular abnormality, abnormalities of respiratory, hepatic, gastrointestinal, renal, or any disorder or history of a condition that would impact or interfere with drug absorption, distribution, metabolism, or excretion during the study or may interfere with the subject's ability to participate in the study.
  5. Subject has family history of early cardiovascular disease or sudden death.
  6. Subject has any history of attempted suicide, clinically significant suicidal ideation based on the Columbia Suicide Severity Rating Scale (C-SSRS) assessment, or answers "yes" to "Suicidal Ideation" item 4 or 5 of any lifetime history on the C-SSRS Children's Lifetime/Recent assessment at screening.
  7. Subject has a known primary sleep disorder (e.g., sleep apnea, narcolepsy, etc.)
  8. If the subject's blood pressure is \< 90th percentile for their age, sex, and height, the single read is sufficient. If the subject's blood pressure is ≥ 90th percentile, two additional reads will be taken, and the three reads will be averaged. If the average of the three readings is ≥ 95th percentile at screening they will be excluded.
  9. Subject is considered treatment by the Investigator or is intolerant to stimulant ADHD medication.
  10. Any use of anticonvulsants currently or within the past 2 years.
  11. Uncontrolled thyroid disorder indicated by thyroid stimulating hormone (TSH) ≤0.8 x the lower limit of normal (LLN) or ≥ 1.25 x the (ULN) from the reference laboratory.
  12. Subject has first-degree relatives (biological parent or sibling) with a history of schizophrenia, schizoaffective disorder, bipolar I disorder, or bipolar II disorder.
  13. Subject has history of substance abuse or shows evidence of substance or has a positive urine drug screen at screening and/or baseline. Subjects with positive drug screens may be allowed to continue in the study if the result of the positive drug screen is from prescribed medications and the subject is willing to washout of the medication as required per protocol.
  14. Previous treatment experience/exposure to CTx-1301.
  15. Subject has a history of allergic reaction or sensitivity to methylphenidate, dexmethylphenidate, or any other substance contained in CTx-1301 or the placebo drug.
  16. Subject has participated in a classroom study within 6 months prior to the start of Screening or has participated in any other clinical study with an drug/product within 30 days prior to Screening or is currently participating in another clinical study.
  17. Subject's family anticipates a move outside the geographic range of the investigative site during the duration of the study period or plans on travel that would not allow compliance to the protocol during the study period.
  18. Subject is unsuitable in any other way, to participate in the study, as determined by the Investigator.
  19. Subject is a family member of an employee at the study center, of the investigator, or those with direct involvement in the proposed study under the direction of that investigator or study center.
  20. Subjects that are siblings are not allowed to be in the same cohort.

Eligibility Criteria (end of dose-optimization phase)

Subjects will be required to meet the following additional eligibility criteria at the end of the dose-optimization phase (Visit 10) to enter into the double-blind, randomized phase. These criteria are based on the efficacy and safety observed over the 8-week dose-optimization period.

  1. A minimum of 2 weeks on optimal dose
  2. A reduction of greater than or equal to 30% reduction of the ADHD-RS-5 from Visit 2 to Visit 10 (plus or minus 3 days) during the dose-optimization phase.
  3. A CGI-I score of 1 or 2 points ("Very much improved" or "Much improved") at the end of the dose optimization phase (Visit 10 (plus or minus 3 days)).
  4. Acceptable tolerability of the optimized CTx-1301 dose during the optimization phase (Visit 2 - Visit 10 (plus or minus 3 days)).
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
45 participants (actual)

Study arms

  • Experimental
    Experimental: 6.25mg CTx-1301 (Dexmethylphenidate tablet)

    All subjects will be titrated to their optimal dose during the dose-optimization phase. Possible doses are 6.25mg, 12.5mg, 18.75mg, 25.0mg, 31.25mg, or 37.5mg. The starting dose for all subjects at Day 0 is 6.25mg. Each subject is expected to be on their optimal dose for 2 sequential weeks prior to the randomization phase. Subjects will be randomized (1:1) to their optimal dose or placebo in the 7-day, double-blind, randomization phase.

    Drug: CTx-1301 - Dexmethylphenidate 6.25mg

  • Experimental
    Experimental: 12.5mg CTx-1301 (Dexmethylphenidate tablet)

    All subjects will be titrated to their optimal dose during the dose-optimization phase. Possible doses are 6.25mg, 12.5mg, 18.75mg, 25.0mg, 31.25mg, or 37.5mg. The starting dose for all subjects at Day 0 is 6.25mg. Each subject is expected to be on their optimal dose for 2 sequential weeks prior to the randomization phase. Subjects will be randomized (1:1) to their optimal dose or placebo in the 7-day, double-blind, randomization phase.

    Drug: CTx-1301 - Dexmethylphenidate 6.25mg · Drug: CTx-1301 - Dexmethylphenidate 12.5mg

  • Experimental
    Experimental: 18.75mg CTx-1301 (Dexmethylphenidate tablet)

    All subjects will be titrated to their optimal dose during the dose-optimization phase. Possible doses are 6.25mg, 12.5mg, 18.75mg, 25.0mg, 31.25mg, or 37.5mg. The starting dose for all subjects at Day 0 is 6.25mg. Each subject is expected to be on their optimal dose for 2 sequential weeks prior to the randomization phase. Subjects will be randomized (1:1) to their optimal dose or placebo in the 7-day, double-blind, randomization phase.

    Drug: CTx-1301 - Dexmethylphenidate 6.25mg · Drug: CTx-1301 - Dexmethylphenidate 12.5mg · Drug: CTx-1301 - Dexmethylphenidate 18.75mg

  • Experimental
    Experimental: 25.0mg CTx-1301 (Dexmethylphenidate tablet)

    All subjects will be titrated to their optimal dose during the dose-optimization phase. Possible doses are 6.25mg, 12.5mg, 18.75mg, 25.0mg, 31.25mg, or 37.5mg. The starting dose for all subjects at Day 0 is 6.25mg. Each subject is expected to be on their optimal dose for 2 sequential weeks prior to the randomization phase. Subjects will be randomized (1:1) to their optimal dose or placebo in the 7-day, double-blind, randomization phase.

    Drug: CTx-1301 - Dexmethylphenidate 6.25mg · Drug: CTx-1301 - Dexmethylphenidate 12.5mg · Drug: CTx-1301 - Dexmethylphenidate 18.75mg · Drug: CTx-1301 - Dexmethylphenidate 25.0mg

  • Experimental
    Experimental: 31.25mg CTx-1301 (Dexmethylphenidate tablet)

    All subjects will be titrated to their optimal dose during the dose-optimization phase. Possible doses are 6.25mg, 12.5mg, 18.75mg, 25.0mg, 31.25mg, or 37.5mg. The starting dose for all subjects at Day 0 is 6.25mg. Each subject is expected to be on their optimal dose for 2 sequential weeks prior to the randomization phase. Subjects will be randomized (1:1) to their optimal dose or placebo in the 7-day, double-blind, randomization phase.

    Drug: CTx-1301 - Dexmethylphenidate 6.25mg · Drug: CTx-1301 - Dexmethylphenidate 12.5mg · Drug: CTx-1301 - Dexmethylphenidate 18.75mg · Drug: CTx-1301 - Dexmethylphenidate 25.0mg · Drug: CTx-1301 - Dexmethylphenidate 31.25mg

  • Experimental
    Experimental: 37.5mg CTx-1301 (Dexmethylphenidate tablet)

    All subjects will be titrated to their optimal dose during the dose-optimization phase. Possible doses are 6.25mg, 12.5mg, 18.75mg, 25.0mg, 31.25mg, or 37.5mg. The starting dose for all subjects at Day 0 is 6.25mg. Each subject is expected to be on their optimal dose for 2 sequential weeks prior to the randomization phase. Subjects will be randomized (1:1) to their optimal dose or placebo in the 7-day, double-blind, randomization phase.

    Drug: CTx-1301 - Dexmethylphenidate 6.25mg · Drug: CTx-1301 - Dexmethylphenidate 12.5mg · Drug: CTx-1301 - Dexmethylphenidate 18.75mg · Drug: CTx-1301 - Dexmethylphenidate 25.0mg · Drug: CTx-1301 - Dexmethylphenidate 31.25mg · Drug: CTx-1301 - Dexmethylphenidate 37.5mg

  • Placebo comparator
    Placebo Comparator: Placebo

    Subjects will be randomized (1:1) to their optimal dose or placebo in the 7-day, double-blind, randomization phase.

    Drug: Placebo

Interventions

  • All subjects will be titrated to their optimal dose during the dose-optimization phase. Possible doses are 6.25mg, 12.5mg, 18.75mg, 25.0mg, 31.25mg, or 37.5mg of CTx-1301.

    Also known as: 6.25mg CTx-1301 (Dexmethylphenidate tablet)

  • All subjects will be titrated to their optimal dose during the dose-optimization phase. Possible doses are 6.25mg, 12.5mg, 18.75mg, 25.0mg, 31.25mg, or 37.5mg of CTx-1301.

    Also known as: 12.5mg CTx-1301 (Dexmethylphenidate tablet)

  • All subjects will be titrated to their optimal dose during the dose-optimization phase. Possible doses are 6.25mg, 12.5mg, 18.75mg, 25.0mg, 31.25mg, or 37.5mg of CTx-1301.

    Also known as: 18.75mg CTx-1301 (Dexmethylphenidate tablet)

  • All subjects will be titrated to their optimal dose during the dose-optimization phase. Possible doses are 6.25mg, 12.5mg, 18.75mg, 25.0mg, 31.25mg, or 37.5mg of CTx-1301.

    Also known as: 25.0mg CTx-1301 (Dexmethylphenidate tablet)

  • All subjects will be titrated to their optimal dose during the dose-optimization phase. Possible doses are 6.25mg, 12.5mg, 18.75mg, 25.0mg, 31.25mg, or 37.5mg of CTx-1301.

    Also known as: 31.25mg CTx-1301 (Dexmethylphenidate tablet)

  • All subjects will be titrated to their optimal dose during the dose-optimization phase. Possible doses are 6.25mg, 12.5mg, 18.75mg, 25.0mg, 31.25mg, or 37.5mg of CTx-1301.

    Also known as: 37.5mg CTx-1301 (Dexmethylphenidate tablet)

  • DrugPlacebo

    Subjects will be randomized (1:1) to their optimal dose or placebo in the 7-day, double-blind, randomized phase.

06

What researchers measure

Primary outcomes

  1. Change from baseline (pre-dose measured at Day 63) of the Swanson, Kotkin, Agler, M-Flynn, and Pelham Scale (SKAMP)-combined scores collected across the 14-hour classroom day.

    The Swanson, Kotkin, Agler, M-Flynn, and Pelham (SKAMP) is a validated rating of subjective impairment of classroom behaviors. It is a 13-item scale, grouped by subcategories of attention, deportment, quality of work, and compliance. Subjects are rated according to a 7-point scale of impairment, with 0 being none and 6 being maximal impairment. A higher SKAMP score signifies greater impairment.

    Time frame: Baseline (pre-dose at Day 63) and at 0.5, 1, 3, 6, 9, 12, 13 and 14 hours post-dose during the full classroom day on Day 63.

Secondary outcomes

  1. Secondary Outcome Measure - Laboratory Classroom Onset and Duration

    Onset and duration of the clinical effect of CTx-1301 during the 14-hour classroom day. The Swanson, Kotkin, Agler, M-Flynn, and Pelham (SKAMP) is a validated rating of subjective impairment of classroom behaviors. It is a 13-item scale, grouped by subcategories of attention, deportment, quality of work, and compliance. Subjects are rated according to a 7-point scale of impairment, with 0 being none and 6 being maximal impairment. A higher SKAMP score signifies greater impairment.

    Time frame: Baseline (pre-dose at Day 63) and at 0.5, 1, 3, 6, 9, 12, 13 and 14 hours post-dose during the full classroom day on Day 63.

  2. Secondary Outcome Measure - CGI-S

    Change from baseline (pre-dose measured at Day 0) of Clinical Global Impression - Severity (CGI-S) scores to CGI-S at Day 63. The CGI-S is a clinician-rated scale that evaluates the severity of ADHD symptoms on a scale from 1 (not at all ill) to 7 (among the most severely ill).

    Time frame: Baseline (pre-dose measured at Day 0) to Day 63 (approximately 9 weeks).

  3. Secondary Outcome Measure - SKAMP

    Mean of the changes from baseline (pre-dose measured at Day 63) of the Swanson, Kotkin, Agler, M-Flynn, and Pelham Scale (SKAMP)-Deportment scores (SKAMP-D) and (SKAMP)-Attention scores (SKAMP-A) collected across the 14-hour classroom day. The Swanson, Kotkin, Agler, M-Flynn, and Pelham (SKAMP) is a validated rating of subjective impairment of classroom behaviors. It is a 13-item scale, grouped by subcategories of attention, deportment, quality of work, and compliance. Subjects are rated according to a 7-point scale of impairment, with 0 being none and 6 being maximal impairment. A higher SKAMP score signifies greater impairment.

    Time frame: Baseline (pre-dose at Day 63) and at 0.5, 1, 3, 6, 9, 12, 13 and 14 hours post-dose during the full classroom day on Day 63.

  4. Secondary Outcome Measure - PERMP-C

    Change from baseline (pre-dose measured at Day 63) of the Permanent Product Measure of Performance - Correct (PERMP-C) scores collected across the 14-hour classroom day.

    Time frame: Baseline (pre-dose at Day 63) and at 0.5, 1, 3, 6, 9, 12, 13 and 14 hours post-dose during the full classroom day on Day 63.

  5. Secondary Outcome Measure - CGI-I

    While CGI-I will be analyzed using the mean change from Baseline (pre-dose at Day 63) compared to Day 63

    Time frame: Baseline (pre-dose at Day 63) compared to Day 63

Other outcomes

  1. Exploratory Endpoints

    Exploratory efficacy endpoints will evaluate the quality and satisfaction of prior medications and of CTx-1301 during screening and D56

    Time frame: • Evaluate overall treatment experience of subjects who have ever taken an ADHD stimulant medication prior to screening (Visit 1) using the entrance questionnaire. • Evaluate overall treatment experience of CTx-1301 at Day 56 (end of dose optimization)

07

Study locations

3 sites
  • Accel Research Sites
    Maitland, Florida 32751, United States
  • Center for Psychiatry & Behavioral Medicine
    Las Vegas, Nevada 89128, United States
  • Coastal Carolina Research Center
    North Charleston, South Carolina 29405, United States
08

References and documents

Individual participant data

Plan to share: No — Overall study data as required by FDAAA801 will be shared upon completion of the study

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jul 2023 (actual). Primary completion is estimated for Feb 2027, 43 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 21, 2023
First posted
Jun 29, 2023
StartActual
Jul 31, 2023
Primary completionEst.
Feb 2027
CompletionEst.
Feb 2027
Last update
May 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 5, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05924594
Lead sponsor
Cingulate Therapeutics
Responsible party
Sponsor
First posted
Jun 29, 2023
Start date
Jul 31, 2023
Primary completion
Feb 2027 (estimated)
Completion
Feb 2027 (estimated)
Last update
May 5, 2026

Study contacts

Matt Brams, MD
study director · Cingulate

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is suspended, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: CTX-1301

Start the discussion